Medtronic Cancer Pain Study Underscores Focus On Infusion Pump Systems
This article was originally published in The Gray Sheet
Executive Summary
Medtronic is looking to combination products incorporating infusion pump systems as another growth vehicle for the firm's top line going into the 2003 fiscal year that began May 1
You may also be interested in...
UK Device Alert Faults Medtronic SynchroMed Supplemental Drug Labeling
Medtronic's SynchroMed implantable drug pump poses medication error risk due to an inaccurate listing of intrathecal drugs, an Oct. 31 device alert by the UK's Medical Devices Agency indicates
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”